Mylan acquires fast-acting, non-opioid painkiller

Mylan (NSDQ:MYL) acquired global development and marketing rights to a fast-acting, non-opioid pain relief drug formulated by Prayog Labs, the company announced today.

The pharma giant is positioning the medication, Meloxicam, as a non-addictive treatment option for patients experiencing acute pain following dentistry procedures or following a surgery.

Prayog Labs has finished initial development work on the product’s formulation, Mylan said, and has conducted pre-clinical studies. Mylan is slated to submit an investigational new drug application t0 the FDA, following a 505(b)(2) pathway.

“We recognize the severity of the opioid crisis as a nationwide public health issue and are committed to doing our part to help in the fight against opioid addiction, abuse and misuse. Offering an alternate, non-opioid pain treatment option represents at least a step toward addressing this national health crisis. We look forward to bringing a novel delivery form of Meloxicam to market for healthcare providers, patients and the public at-large who are affected by this epidemic,” CEO Heather Bresch said in prepared remarks.

“Adding a fast-acting Meloxicam to our pipeline is meaningful not because it will be a key growth driver, but because it’s the right thing to do,” president Rajiv Malik added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Only a Few More Days to Register for the most anticipated conference of the winter! DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry. Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry. REGISTER NOW Use code LASTCHANCE to save an additional 20%.